Abstract
Background-Un-engineered human and rat umbilical cord matrix stem cells (rUCMSC) attenuate growth of several types of tumors in mice and rats. However, the mechanism by which UCMSC attenuate tumor growth has not been studied rigorously.
Methods-The possible mechanisms of tumor growth attenuation by rUCMSC were studied using orthotopic Mat B III rat mammary tumor grafts in female F344 rats. Tumor-infiltrating leukocytes were identified and quantified by immunohistochemical image analysis. Potential cytokines involved in lymphocyte infiltration in the tumors were determined by microarray and Western blot analysis. The Boyden chamber migration assay was performed for the functional analysis of identified cytokines.
Results-rUCMSC markedly attenuated the tumor growth; this attenuation was accompanied by considerable lymphocyte infiltration. Immunohistochemical analysis revealed that the majority of infiltrating lymphocytes in the rUCMSC-treated tumors were CD3+ T cells. In addition, treatment with rUCMSC significantly increased infiltration of CD 8+ and CD4+ T cells and NK cells throughout tumor tissue. CD68+ monocytes/macrophages and FoxP3+ regulatory T cells were scarcely observed, only in the tumors of the PBS control group. Microarray analysis of rUCMSC identified that monocyte chemotactic protein (MCP)-1 is involved in rUCMSCinduced lymphocyte infiltration in the tumor tissues.
Discussion-These results suggest that naïve rUCMSC attenuated mammary tumor growth at least in part by enhancing host anti-tumor immune responses. Thus, naïve UCMSC can be used as powerful therapeutic cells for breast cancer treatment, and MCP-1 may be a key molecule to enhance the effect of UCMSC at the tumor site.
We have isolated a cell line from the Wharton's jelly of rat umbilical cord, termed rat umbilical cord matrix stem cells (rUCMSC) (1) . Characteristics of this rUCMSC are similar to those isolated from human umbilical cord matrix and bone marrow (2, 3) . Both human and rUCMSC exhibit tumor tropism (4) (5) (6) . Human UCMSC have proven to be useful as gene delivery vehicles for targeted gene therapy (4, 6) . We previously discovered that intratumoral (i.t.) or intravenous (i.v.) injection of naïve rUCMSC is capable of causing complete regression of rat mammary tumors in immunocompetent rats (1) . Recent studies also indicated that naïve human UCMSC alone possess a strong tumoricidal activity against human breast carcinoma cells in immunodeficient mice (5, 7) . Both human and rUCMSC have been shown to induce apoptosis and cell cycle arrest in co-cultured tumor cells by UCMSC-produced tumor cell growth regulators (1, 5, 7) . Genome-wide microarray analysis revealed that these growth regulators are potentially associated with multiple tumor suppressor gene products (8) and cell motilityassociated genes (7).These results suggest that naïve UCMSC can be used for cytotherapy for mammary tumors. However, the mechanism by which UCMSC control tumor growth in immunocompetent animals is yet to be completely understood.
The tumor microenvironment, composed of various cell types such as endothelial cells, tumor-infiltrating leukocytes (TILs), fibroblasts and extracellular matrix (ECM), is important in regulating tumor growth (9-13). Fleming et al. (13) have shown that breast ECM has an ability to increase the aggressiveness and tumorigenicity of breast cancer cells. However, a suppressive role for stromal cells in the tumor microenvironment is also reported (14) (15) (16) (17) . Among components in the tumor microenvironment, TILs play an important role in tumor attenuation (18, 19) . Particularly, two subsets of lymphocytes, CD8+ T cells and natural killer (NK) cells, are suggested to be involved in tumor attenuation by directly damaging tumor cells (19, 20 ) . This is supported by the reports that TILs can provide a survival advantage to various cancer patients (20) (21) (22) (23) (24) . In contrast, regulatory T (Treg) cells, a subpopulation of T cells that have the ability to suppress both CD4+ and CD8+ T cell functions (25) indirectly support tumor growth by suppressing tumor-specific CD8+ T cells (26) .
Although both naïve human and rUCMSC exhibited strong tumoricidal activity against breast carcinoma cells, a bolus treatment with rUCMSC caused complete tumor regression in immunocompetent rats (1), whereas human UCMSC did not show such powerful tumor growth attenuation effects in an animal study in immunodeficient mice; human UCMSC treatment reduced tumor burden by 50% (5) . These studies prompted us to speculate an involvement of tumor immune response in rUCMSC-dependent strong tumoricidal activity, since immunocompetent animals were used only for the rUCMSC study. In support of this speculation, lymphocyte infiltration in tumor tissues has been shown to be well-correlated with good clinical outcomes in human patients receiving tumor antigen-activated CD8+ T cell infusions for metastatic melanoma (27) .
In the present study, we attempted to clarify the mechanisms by which naïve rUCMSC attenuate/regress tumor growth in vivo and in vitro. Here we report for the first time that treatment with rUCMSC significantly increases lymphocyte infiltration in the tumor tissues, and that TILs, primarily CD8+ T cells and NK cells, induce tumor cell death, thereby regressing tumors. The primary mechanism by which rUCMSC caused significant lymphocyte infiltration in the tumor tissues appears to be due to the increased monocyte chemotactic protein (MCP)-1 secretion from rUCMSC that had homed tumor tissues.
Materials and Methods
Cell culture rUCMSC were harvested from E19 pregnant rats. The method to isolate and culture rUCMSC was previously described (1) . rUCMSC were maintained in low-serum (defined) medium, containing the following mixture per 100 mL: 57 mL low-glucose DMEM (Invitrogen, Carlsbad, CA), 37 mL MCBD 201 (Sigma-Aldrich, St. Louis, MO), 2 mL fetal bovine serum (FBS; Atlanta Biologicals, Inc., Lawrenceville, GA), 1 mL of 100x insulin-transferrin-selenium-X (Invitrogen); 1 mL of 0.15 g/mL AlbuMax I (Invitrogen), 1 mL of 100 x Pen/Strep (Invitrogen), 10 nmol/L dexamethasone (Sigma), 100 µmol/L ascorbic acid 2-phosphate (Sigma), 10 ng/mL epidermal growth factor (R&D Systems, Minneapolis, MN), and 10 ng/mL platelet derived growth factor-BB (R&D Systems). Cells were maintained at 37 in a humidified atmosphere containing 5% CO 2 . The rat mammary adenocarcinoma cell line, Mat B III (American Type Culture Collection, Manassas, VA), was maintained in McCoy's 5A modified medium (Invitrogen) supplemented with 10% FBS, 100 units/mL penicillin, and 100 µg/mL streptomycin (Invitrogen). Cells were cultured at 37 in a humidified atmosphere containing 5% CO 2 .
In vivo studies
All experiments were carried out using protocols approved by the Institutional Animal Care and Use Committee of Kansas State University (#2681). ) suspended in 100 µL of PBS were injected i.t. Tumor bearing rats given i.t. 100 µL of PBS on day 4 served as control rats. Tumors became palpable starting from day 7; tumors were measured every 3 to 4 days with calipers under isoflurane anesthesia. A portion of rUCMSC treated rats (5 rats) and PBS treated rats were sacrificed 14 days after tumor cell inoculation.
Tumor tissues were removed, fixed in 10% buffered neutral formalin, and used for histological and immunohistochemical analysis. Fresh-frozen tissue was also prepared using O.C.T.
Compound (Sakura Finetek USA, Torrance, CA). The remaining 4 rUCMSC-treated rats were used for the monitoring of the tumor size until the tumor size was insignificant.
Microarray analysis
To examine chemoattractant gene expression, a microarray study was conducted comparing ) were added to the insert on the following day. After 48 hours coculture, total RNAs were isolated using TRIzol Reagent (Invitrogen) following the manufacturer's instructions. Quality and quantity of total RNA samples were assessed using an Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA). The microarray analysis, including quality control, was conducted by the Gene Expression and Genomics Unit at the National Institute on Aging (NIA) using RatRef-12 BeadChip (Illumina, San Diego, CA). For each sample, biotinylated cRNAs were prepared using an Illumina total prep RNA amplification kit (Applied Biosystems, Foster City, CA, USA). Overall microarray analysis was carried out according to the method described previously (28) . Statistical analysis was processed using a Z score developed at NIA (29) . Z scores were calculated by subtracting the average gene intensity from the raw intensity data for each gene and dividing that result by the S.D. of all the measured intensities. Gene expression differences between any two experiments were calculated by taking the difference between the observed gene Z scores. Genes relevant to cell migration, such as chemokines and cytokines, which showed 1.5 times higher expression than in the control group, were selected for the final gene list.
Cell migration assay
Migration of peripheral blood mononuclear cells (PBMC) was carried out using Transwell cell culture plates with 5 µm pores (Corning) according to the previously described method (30) 
Histological analysis
Paraffin-embedded mammary tumor tissues were sectioned at 4 µm and stained with hematoxylin and eosin for histological examination. Some unstained sections were selected for immunohistochemistry to determine the CD antigens on the lymphocytes in the tumor tissues.
Slides were deparaffinized and rehydrated before staining. The heat-induced antigen unmasking was performed in citrate buffer for 5 minutes using an autoclave. Sections were then incubated with 3 % hydrogen peroxide in methanol for 3 minutes to block endogenous peroxide activity. 
Statistical analysis
All data are reported as mean ± SE. Data were analyzed by Student t test. Group comparisons were deemed significant for 2-tailed P values below 0.05. Fig. 1A ). The tumor growth reached a peak at the 16-19 days after tumor inoculation and regressed thereafter. Tumor size was insignificant 40 days after tumor cell inoculation. In PBS-injected control rats, the tumors grew continuously; rats were sacrificed 14 days after tumor inoculation. To evaluate leukocyte infiltration in the tumor tissues, a portion of rats were sacrificed at 14 days after tumor cell inoculation and tumor tissues were removed for immunohistochemical analysis. The tumor weights measured on day 14 showed a significant difference between rUCMSC-and PBSinjected groups (Fig. 1B) .
Results

rUCMSC treatment stimulated infiltration of numerous lymphocytes into the tumor
As shown in Fig. 2A , PBS-treated orthotopic tumors in the mammary fat pad were composed of solidly packed round to oval cells. All tumor cells had irregularly-shaped and-sized nuclei with prominent nucleoli. A large number of mitotic figures were also commonly observed. rUCMSC treatment significantly increased the amount of ECM deposition and decreased the number of tumor cells within the tumor tissues (Fig. 2B) . In addition, rUCMSC treatment caused infiltration of numerous lymphocytes, but only a small number of neutrophils, in the peritumoral area of the tumor mass. This leukocyte infiltration was not observed in the PBS control group (Fig. 2A) . (Fig. 3) . In the subpopulation of T cells, treatment with rUCMSC significantly increased the number of both CD4+ (3 fold) and CD8+ cells (2 fold, Fig. 3 ). The average number of CD8+ cells was higher than that of CD4+ cells. On the contrary, a small number of Foxp3+ cells were observed only in the PBS group, but not in the rUCMSC treated group (Fig. 3) . Although NK cells were not a major component of theTILs, NK cells were also significantly higher (1.8 fold higher) in the rUCMSC treated group than in the control group. Interestingly, CD68+ cells were infrequently observed only in the PBS group, but not in the tumors treated with rUCMSC (Fig. 3) . These results indicate that rUCMSC treatment caused the tumor tissue infiltration of helper and cytotoxic T cells and NK cells, but decreased Treg cells and monocytes/macrophages.
Microarray analysis of cytokines related for cell migration
Gene expression of rUCMSC co-cultured with Mat B III was compared with naïve rUCMSC. A partial list of the highly up-or down-regulated chemokines, cytokines and immune cell migration-related genes which showed more than 1.5 times difference in Z-ratio is presented in Table 2 . Notably, expression of MCP-1 was significantly increased in rUCMSC (13.88 fold) when they were co-cultured with Mat B III cells. Since MCP-1 is a one of the chemoattractants associated with lymphocyte infiltration, MCP-1 is a potential candidate for stimulating lymphocyte migration into the rUCMSC-treated tumors.
MCP-1 expression is increased in rUCMSC when they were co-cultured with Mat B III cells
To confirm the above mRNA expression results from microarray analysis in protein levels, the expression of MCP-1 was semi-quantified by Western blot analysis. As shown in Fig. 4 , the basal expression of MCP-1 in rUCMSC was significantly larger than that in Mat B III. Furthermore, the expression of the MCP-1 in rUCMSC was significantly increased when they were cocultured with Mat B III cells. These results suggest that MCP-1 expression is sensitively upregulated in response to the presence of Mat B III mammary carcinoma cells.
rUCMSC stimulated PBMC migration by MCP-1 secretion
To examine whether PBMC migrate toward rUCMSC and whether this migration is controlled by MCP-1, PBMC migration was examined by the Boyden chamber assay using Transwell culture system in the presence or absence of MCP-1 neutralizing antibody. As shown in The present study showed that treatment with naive rUCMSC significantly attenuated the growth of orthotopic rat mammary tumors (Fig. 1) . This is consistent with the previous reports (1), in which a single treatment with rUCMSC completely abolished rat mammary tumors. Immunohistochemical analysis of tumor tissues treated with rUCMSC revealed a significant increase of lymphocyte infiltration in the tumor tissues (Fig. 2) . Detailed analysis further revealed that the major component of infiltrating lymphocytes in rUCMSC-treated tumor tissues is CD8+ cells (approximately 52% of total lymphocytes are CD8+ T cells and 37.5 % cells correspond to CD4+ T cells, Fig. 3 ). Although CD20+ cells were also increased in the rUCMSC treated tumors, CD20+ cells comprised less than 12% of total lymphocytes (Fig. 3) . In addition, a unique discovery in the present study was that no CD68+ or Foxp3+ cells were detected in tumor tissues in rUCMSC-treated mice (Fig. 3E) In the present study, rUCMSC treatment also increased NK cells in tumor tissues ( Our results from the present study indicate that rat PBMC migration is directed toward rUCMSC rather than Mat B III mammary carcinoma cells (Fig. 5) . This migration is associated with MCP-1, as MCP-1 neutralizing antibody attenuates PBMC migration to the rUCMSC (Fig.   5 ). This is directly relevant to the histological findings showing that i.t. injection of rUCMSC induced infiltration of numerous lymphocytes into the tumor tissues (Figs. 2 and 3 Interestingly, CD68+ cells were not observed in the rUCMSC-treated tumors despite the fact that CD68+ macrophages are known to be attracted by MCP-1 (42) . The likely explanation is that a factor inhibitory to macrophages might be secreted from rUCMSC or Mat B III cells.
Indeed, the microarray analysis indicated that the expression of macrophage inhibitory factor (MIF) was significantly increased (3.4 fold) in rUCMSC co-cultured with Mat B III cells (Table   1) . Therefore, it is likely that increased MIF expression may have stimulated an exodus of macrophages from the rUCMSC-treated tumors, thus assisting rUCMSC-dependent attenuation of tumor growth. Clarification of the role of MIF in rUCMSC-treated tumors requires further studies.
Regarding macrophage infiltration in the tumor tissues, clinical studies have sought to identify correlations between macrophage density and prognosis. A summary in a review by Bingle et al. (43) using a meta-analysis showed that in >80% of the cases, an increased macrophage density in tumor tissues was associated with poor prognosis, and the remaining 20% of cases were split between having no effect and those with good prognosis. This was confirmed with simple histological evaluation of macrophage density, which showed that macrophage density in itself was an independent predictor of poor outcome (44, 45) . In consideration of these reports, the microenvironment without macrophages results in a better probability for attenuating tumor growth. However, further experiments are required to clarify the relationship between the decrease of macrophage density and the effect of rUCMSC on tumor growth attenuation.
Among many tissue-originated multipotent stem cells, UCMSC are very usable due to unethical abundant resources, the simplicity of their preparation method (46) , bankability (47), low immunogenicity (48, 49) , and tropism to inflammatory tissues such as tumor tissues (1, 4, 6) etc. In particular, human UCMSC apparently escape the host immune responses by multiple mechanisms (8); they express MHC class I but not class II antigens; they are negative for other co-stimulatory antigens such as CD80 and CD86 (50, 51); they produce large amounts of tolerogenic interleukin-10 and transforming growth factor-β and express human leukocyte antigen G (HLA-G) at higher levels than bone marrow derived mesenchymal stem cells (50) (51) (52) .
This poor immunogenicity allows human UCMSC to be usable for allogeneic transplantation in potential human applications. In relation to this poor immunogenicity, it is noteworthy to cite that Chao et al. have reported a successful transplantation of human UCMSC-derived islet-like cells in diabetic rats without using immunosuppressants (53) . The tropism of UCMSC to the inflammatory tissues, such as tumor tissues, make this cell also usable as targeted drug or gene delivery vehicles. Recent reports have shown that human UCMSC engineered to express interferon (IFN)-β, which is a strong apoptosis inducer, shown to be migrated to metastatic human breast tumor nodules in the lung (4) or to the bronchioloalveolar carcinoma nodules (6) , 
